Multi Cancer Early Detection Global Market Report 2024

The multi cancer early detection market size has grown rapidly in recent years. It will grow from $1.22 billion in 2023 to $1.45 billion in 2024 at a compound annual growth rate (CAGR) of 19%. The growth in the historic period can be attributed to government initiatives and funding, increasing prevalence of cancer, expansion of healthcare infrastructure, growing awareness about early cancer detection, rising adoption of personalized medicine, decreasing costs of genetic testing.

The multi cancer early detection market size is expected to see rapid growth in the next few years. It will grow to $2.93 billion in 2028 at a compound annual growth rate (CAGR) of 19.2%. The projected expansion in the forecast period can be credited to the wider adoption of telemedicine and digital health, an increasing focus on preventive healthcare measures, the rising uptake of precision oncology practices, advancements in biomarker exploration, and a surge in direct-to-consumer genetic testing. Key trends anticipated in the forecast period encompass the heightened utilization of AI and machine learning, the growing acceptance of liquid biopsy methodologies, the integration of multi-omics strategies, the proliferation of at-home testing kits, an increased emphasis on early-stage cancer detection, and the innovation of minimally invasive diagnostic techniques.

The increasing adoption of personalized medicine is poised to drive the expansion of the multi-cancer early detection market in the future. Personalized medicine, which customizes healthcare interventions based on individual characteristics and genetic makeup, is gaining traction due to its ability to enhance treatment efficacy. This trend is fueled by advancements in genomics, the growing complexity of diseases, and supportive regulatory frameworks. Personalized medicine amplifies the effectiveness of multi-cancer early detection by tailoring screening and treatment approaches to individual genetic and biomarker profiles. For instance, in February 2024, the FDA approved 16 novel personalized therapies for rare diseases, up from six in 2022, including seven cancer treatments and three for various other conditions, as reported by the Personalized Medicine Coalition. Hence, the increasing embrace of personalized medicine is fostering growth in the multi-cancer early detection market.

Major companies in the multi-cancer early detection market are innovating ctDNA-based liquid biopsy tests to improve sensitivity, specificity, and early detection rates, ultimately enhancing patient outcomes. These tests detect circulating tumor DNA in the bloodstream, offering a non-invasive method to track tumor dynamics, treatment response, and early recurrence or minimal residual disease. For example, in May 2023, Lucence, a US-based cancer diagnostics firm, unveiled LucenceINSIGHT, a pioneering multi-cancer early detection (MCED) blood test, at their US headquarters. This ctDNA-based liquid biopsy test enables screening for 10 common cancers using a single blood sample. With approximately 78% of global cancer deaths linked to types lacking routine screening protocols, this blood test offers improved convenience and accessibility for asymptomatic individuals seeking screening for various cancer types.

In August 2021, Illumina Inc., a US-based biotech firm renowned for genetic sequencing and array-based technologies, acquired Grail Inc. for an undisclosed sum. This acquisition was driven by Illumina's ambition to expedite patient access to a vital multi-cancer early detection test. The strategic objective was to transform cancer management by enhancing the accessibility of this genomic test, thereby advancing human health through the genome's potential. Grail Inc., based in the US, specializes in crafting tests for the early detection of various cancer types.

Major companies operating in the multi cancer early detection market are Illumina Inc., Sysmex Inostics GmbH, Exact Sciences Corporation, Natera Inc, Guardant Health, Core Diagnostics, Genecast Biotechnology Co. Ltd, Burning Rock Biotech Limited, Freenome Holdings Inc., Guangzhou AnchorDx Medical Co. Ltd, Singlera Genomics Incorporated, Naveris Inc., Lucence Health Inc., PredOmix Technologies, Micronoma INC., EarlyDiagnostics (EarlyDx), Elypta AB, Predictive Oncology, ANPAC Bio-Medical Science Co. Ltd, CanSense Ltd, Epigenomics AG, VolitionRX, OncoSeek, Laboratory for Advanced Medicine, Inc., AnchorDx.

North America was the largest region in the multi cancer early detection market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multi cancer early detection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the multi cancer early detection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Multi-cancer early detection involves identifying and diagnosing various cancer types in their early stages through the examination of biomarkers and other indicators present in bodily fluids or tissues. The objective is to detect cancerous conditions affecting multiple organs or tissues before symptoms appear, thereby facilitating prompt intervention and enhancing treatment effectiveness.

The primary categories of multi-cancer early detection include liquid biopsy, gene panels, laboratory-developed tests (LDT), and other methodologies. Liquid biopsy, for instance, is a non-invasive diagnostic procedure that identifies cancer-related biomarkers, such as circulating tumor cells (CTCs) or cell-free DNA (cfDNA), from bodily fluids such as blood or urine. These tests provide valuable information on cancer detection, progression, and response to treatment. They are utilized across hospitals, diagnostic facilities, and other medical settings for diagnosing various cancer types, including both solid tumors and hematological malignancies.

The multi cancer early detection market research report is one of a series of new reports that provides multi cancer early detection market statistics, including the multi cancer early detection industry global market size, regional shares, competitors with multi cancer early detection market share, detailed multi cancer early detection market segments, market trends, and opportunities, and any further data you may need to thrive in the multi cancer early detection industry. This multi cancer early detection market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The multi-cancer early detection market consists of revenues earned by entities by providing services such as diagnostic imaging, screening tests, molecular diagnostics, and risk assessment services. The market value includes the value of related goods sold by the service provider or included within the service offering. The multi-cancer early detection market also includes sales of assay panels, diagnostic kits, reagents, instruments, software solutions for data analysis and interpretation, and quality control materials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.